What is HC Wainwright’s Estimate for INTS Q3 Earnings?

Intensity Therapeutics Inc. (NASDAQ:INTS) – Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Intensity Therapeutics in a report released on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($1.11) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.77) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.54) EPS.

Other equities research analysts have also issued research reports about the stock. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Intensity Therapeutics Trading Down 0.2%

Shares of INTS stock opened at $4.20 on Thursday. The business has a 50-day moving average of $4.28 and a 200 day moving average of $5.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. Intensity Therapeutics has a 1-year low of $3.51 and a 1-year high of $43.50. The stock has a market capitalization of $13.69 million, a PE ratio of -1.18 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24).

Institutional Investors Weigh In On Intensity Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after acquiring an additional 51,000 shares during the last quarter. Legacy Advisors LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter valued at approximately $63,000. State Street Corp boosted its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares during the period. Finally, Corient Private Wealth LLC purchased a new position in shares of Intensity Therapeutics during the 4th quarter worth about $41,000. 3.74% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Intensity Therapeutics

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $7 from $5 and reiterated a “Buy” rating. The new target implies substantial upside from recent trading levels and is the clearest positive development for Intensity Therapeutics. StreetInsider analyst commentary
• Positive Sentiment: HC Wainwright projected quarterly 2027 losses of $0.21 to $0.26 per share while maintaining its Buy rating and $7 target. Although the estimates still reflect ongoing losses, the valuation stance suggests the firm expects longer-term potential from the company’s pipeline. MarketBeat analyst estimates
• Neutral Sentiment: Brookline Capital Markets raised its FY2030 EPS forecast to $13.27 from $12.72, indicating significant long-term earnings potential if Intensity Therapeutics’ development programs succeed. However, this forecast is distant and may have limited immediate influence on trading.
• Negative Sentiment: Brookline lowered its EPS forecasts for FY2026, FY2027 and FY2028 to losses of $3.41, $2.41 and $6.01 per share, respectively. It also cut its Q3 and Q4 2026 estimates to losses of $0.77 and $0.71 per share, signaling expectations for greater near-term cash burn and weaker profitability. MarketBeat Brookline Capital Markets estimates

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.